SAB Biotherapeutics Inc (SABS) Cotización

SABS under $5

SABS under $4

SABS 10Q due 4/9

My swinger is aliveeee

1.11 High PM

Moving PM

Historic short interest:

You can go to this link to check short interest in a stock:
http://nasdaqtrader.com/Trader.aspx?id=ShortInterest

Publication schedule is here:
http://nasdaqtrader.com/Trader.aspx?id=ShortIntPubSch

Settlement Date Short Interest Percent Change
Average Daily Share Volume Days to Cover

04/29/2022 265,130 3.69 81,665 3.25
04/14/2022 255,684 (12.79) 228,946 1.12
03/31/2022 293,187 (6.75) 738,191 1.00
03/15/2022 314,404 (29.98) 157,964 1.99
02/28/2022 448,992 (5.86) 58,365 7.69
02/15/2022 476,960 (0.10) 52,712 9.05
01/31/2022 477,414 19.75 101,581 4.70
01/14/2022 398,689 (26.89) 116,486 3.42
12/31/2021 545,364 161.07 394,602 1.38
12/15/2021 208,899 6.06 315,978 1.00
11/30/2021 196,960 11.21 424,546 1.00
11/15/2021 177,107 2124.40 808,889 1.00
10/29/2021 7,962 (83.75) 1,857,416 1.00
10/15/2021 49,012 233.69 352,134 1.00
09/30/2021 14,688 (25.95) 119,242 1.00
09/15/2021 19,834 26.07 16,674 1.19
08/31/2021 15,733 (11.53) 18,667 1.00
08/13/2021 17,784 (52.59) 26,087 1.00
07/30/2021 37,510 (51.73) 21,437 1.75
07/15/2021 77,706 904.34 59,460 1.31
06/30/2021 7,737 (32.19) 29,894 1.00
06/15/2021 11,409 (64.02) 8,295 1.38
05/28/2021 31,708 270.85 7,999 3.96
05/14/2021 8,550 (16.24) 27,827 1.00
04/30/2021 10,208 11.62 89,060 1.00
04/15/2021 9,145 495.77 6,454 1.42
03/31/2021 1,535 148.78 65,155 1.00
03/15/2021 617 (99.39) 52,716 1.00
02/26/2021 101,294 12853.20 100,564 1.01
02/12/2021 782 22,705 1.00

Another great trade.$$$ Up up we go!

SAB’s government contract work is expected to provide up to an additional $91.7 million in funding. Due to the structure of the contracts, these funds are not reflected on the balance sheet.

Historic short interest:

You can go to this link to check short interest in a stock:
http://nasdaqtrader.com/Trader.aspx?id=ShortInterest

Publication schedule is here:
http://nasdaqtrader.com/Trader.aspx?id=ShortIntPubSch

Settlement Date Short Interest Percent Change
Average Daily Share Volume Days to Cover

02/28/2022 448,992 (5.86) 58,365 7.69
02/15/2022 476,960 (0.10) 52,712 9.05
01/31/2022 477,414 19.75 101,581 4.70
01/14/2022 398,689 (26.89) 116,486 3.42
12/31/2021 545,364 161.07 394,602 1.38
12/15/2021 789,079 (37.70) 809,014 1.00
11/30/2021 1,266,672 (30.75) 737,652 1.72
11/15/2021 177,107 2124.40 808,889 1.00
10/29/2021 7,962 (83.75) 1,857,416 1.00
10/15/2021 49,012 233.69 352,134 1.00
09/30/2021 14,688 (25.95) 119,242 1.00
09/15/2021 19,834 26.07 16,674 1.19
08/31/2021 15,733 (11.53) 18,667 1.00
08/13/2021 17,784 (52.59) 26,087 1.00
07/30/2021 37,510 (51.73) 21,437 1.75
07/15/2021 77,706 904.34 59,460 1.31
06/30/2021 7,737 (32.19) 29,894 1.00
06/15/2021 11,409 (64.02) 8,295 1.38
05/28/2021 31,708 270.85 7,999 3.96
05/14/2021 8,550 (16.24) 27,827 1.00
04/30/2021 10,208 11.62 89,060 1.00
04/15/2021 9,145 495.77 6,454 1.42
03/31/2021 1,535 148.78 65,155 1.00
03/15/2021 617 (99.39) 52,716 1.00
02/26/2021 101,294 12853.20 100,564 1.01
02/12/2021 782 22,705 1.00

Historic short interest:

You can go to this link to check short interest in a stock:
http://nasdaqtrader.com/Trader.aspx?id=ShortInterest

Publication schedule is here:
http://nasdaqtrader.com/Trader.aspx?id=ShortIntPubSch

Settlement Date Short Interest Percent Change
Average Daily Share Volume Days to Cover

01/14/2022 398,689 (26.89) 116,486 3.42
12/31/2021 545,364 161.07 394,602 1.38
12/15/2021 789,079 (37.70) 809,014 1.00
11/30/2021 1,266,672 (30.75) 737,652 1.72
11/15/2021 177,107 2124.40 808,889 1.00
10/29/2021 7,962 (83.75)1,857,416 1.00
10/15/2021 49,012 233.69 352,134 1.00
09/30/2021 14,688 (25.95) 119,242 1.00
09/15/2021 19,834 26.07 16,674 1.19
08/31/2021 15,733 (11.53) 18,667 1.00
08/13/2021 17,784 (52.59) 26,087 1.00
07/30/2021 37,510 (51.73) 21,437 1.75
07/15/2021 77,706 904.34 59,460 1.31
06/30/2021 7,737 (32.19) 29,894 1.00
06/15/2021 11,409 (64.02) 8,295 1.38
05/28/2021 31,708 270.85 7,999 3.96
05/14/2021 8,550 (16.24) 27,827 1.00
04/30/2021 10,208 11.62 89,060 1.00
04/15/2021 9,145 495.77 6,454 1.42
03/31/2021 1,535 148.78 65,155 1.00
03/15/2021 617 (99.39) 52,716 1.00
02/26/2021 101,294 12853.20 100,564 1.01
02/12/2021 782 22,705 1.00

Historic short interest:

You can go to this link to check short interest in a stock:
http://nasdaqtrader.com/Trader.aspx?id=ShortInterest

Publication schedule is here:
http://nasdaqtrader.com/Trader.aspx?id=ShortIntPubSch

Settlement Date Short Interest Percent Change
Average Daily Share Volume Days to Cover

12/15/2021 789,079 (37.70) 809,014 1.00
11/30/2021 1,266,672 (30.75) 737,652 1.72
11/15/2021 177,107 2124.40 808,889 1.00
10/29/2021 7,962 (83.75) 1,857,416 1.00
10/15/2021 49,012 233.69 352,134 1.00
09/30/2021 14,688 (25.95) 119,242 1.00
09/15/2021 19,834 26.07 16,674 1.19
08/31/2021 15,733 (11.53) 18,667 1.00
08/13/2021 17,784 (52.59) 26,087 1.00
07/30/2021 37,510 (51.73) 21,437 1.75
07/15/2021 77,706 904.34 59,460 1.31
06/30/2021 7,737 (32.19) 29,894 1.00
06/15/2021 11,409 (64.02) 8,295 1.38
05/28/2021 31,708 270.85 7,999 3.96
05/14/2021 8,550 (16.24) 27,827 1.00
04/30/2021 10,208 11.62 89,060 1.00
04/15/2021 9,145 495.77 6,454 1.42
03/31/2021 1,535 148.78 65,155 1.00
03/15/2021 617 (99.39) 52,716 1.00
02/26/2021 101,294 12853.20 100,564 1.01
02/12/2021 782 22,705 1.00

Historic short interest:

You can go to this link to check short interest in a stock:
http://nasdaqtrader.com/Trader.aspx?id=ShortInterest

Publication schedule is here:
http://nasdaqtrader.com/Trader.aspx?id=ShortIntPubSch

Settlement Date Short Interest Percent Change
Average Daily Share Volume Days to Cover

11/15/2021 177,107 2124.40 808,889 1.00
10/29/2021 7,962 (83.75) 1,857,416 1.00
10/15/2021 49,012 233.69 352,134 1.00
09/30/2021 14,688 (25.95) 119,242 1.00
09/15/2021 19,834 26.07 16,674 1.19
08/31/2021 15,733 (11.53) 18,667 1.00
08/13/2021 17,784 (52.59) 26,087 1.00
07/30/2021 37,510 (51.73) 21,437 1.75
07/15/2021 77,706 904.34 59,460 1.31
06/30/2021 7,737 (32.19) 29,894 1.00
06/15/2021 11,409 (64.02) 8,295 1.38
05/28/2021 31,708 270.85 7,999 3.96
05/14/2021 8,550 (16.24) 27,827 1.00
04/30/2021 10,208 11.62 89,060 1.00
04/15/2021 9,145 495.77 6,454 1.42
03/31/2021 1,535 148.78 65,155 1.00
03/15/2021 617 (99.39) 52,716 1.00
02/26/2021 101,294 12853.20 100,564 1.01
02/12/2021 782 22,705 1.00

Monoclonal antibodies vs polyclonal antibodies:




https://www.sabbiotherapeutics.com/sab-science/

Video on home page - not youtube so I can't link to it.

https://www.sabbiotherapeutics.com/

Big Cypress Acquisition Corp Announces Special Meeting of Stockholders to Approve Business Combination with SAB Biotherapeutics
Registration Statement on Form S-4 Has Been Declared Effective by Securities and Exchange Commission

Stockholder Vote Scheduled for October 20, 2021

NEWS PROVIDED BY

Big Cypress Acquisition Corp
Sep 23, 2021, 07:00 ET

SHARE THIS ARTICLE

MIAMI, Sept. 23, 2021 /PRNewswire/ -- Big Cypress Acquisition Corp (NASDAQ: BCYP), (Big Cypress) a publicly-traded special purpose acquisition company focused on innovative biopharmaceutical firms, today announced that it will hold a Special Meeting of stockholders (the "Special Meeting") to, among other matters, allow its stockholders to approve the proposed business combination (the "Business Combination") with SAB Biotherapeutics, Inc., (SAB), a clinical-stage biopharmaceutical company developing a novel immunotherapy platform producing targeted, high potency, fully-human polyclonal antibody therapeutics and advancing programs in infectious disease, immune system disorders and oncology. On September 22, 2021, the Securities and Exchange Commission ("SEC") declared effective Big Cypress' registration statement on Form S-4 (as amended, the "Registration Statement"), which includes a definitive proxy statement in connection with the Special Meeting of Big Cypress' stockholders. Big Cypress and SAB entered into a definitive agreement relating to the business combination on June 22, 2021, that would result in SAB becoming a public company upon the closing of the transaction.

The Special Meeting is scheduled to be held on October 20, 2021, at 10:00 a.m., Eastern Time, and will be conducted virtually via live webcast. Holders of record of Big Cypress' common stock at the close of business on the record date of September 17, 2021, may vote at the Special Meeting.

Upon the closing of the business combination, the combined company will be named SAB Biotherapeutics, Inc. (the "Combined Company"). The parties expect that the Combined Company's common stock and warrants will be listed on the Nasdaq Stock Exchange under the ticker symbols "DIVR" and "DIVRW," respectively.

Big Cypress stockholders who need assistance voting or have questions regarding the Special Meeting may contact Big Cypress' proxy solicitor, Kingsdale Advisors, by telephone toll-free at (800) 775-1986 or by email at contactus@kingsdaleadvisors.com. Banks and brokerage firms may call (416) 867-2272.

About Big Cypress Acquisition Corp.
Big Cypress Acquisition Corp. is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses with a focus within the life sciences industry. Big Cypress is led by Chief Executive Officer, Chief Financial Officer and Director Samuel J. Reich. For more information, visit www.bigcypressaccorp.com.

About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully-human polyclonal antibodies. SAB has applied advanced genetic engineering and antibody science to develop transchromosomic (Tc) Bovine™ herds that produce fully-human antibodies targeted at specific diseases, including infectious diseases such as COVID-19 and influenza, immune system disorders including type 1 diabetes and organ transplantation, and cancer. SAB's versatile DiversitAb™ platform is applicable to a wide range of serious unmet needs in human diseases. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB is currently advancing multiple clinical programs and has a number of collaborations with the US government and global pharmaceutical companies. For more information on SAB, visit: www.sabbiotherapeutics.com and follow @SABBantibody on Twitter.

Forward-Looking Statements
Certain statements made herein that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook" and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding future events, the development of SAB-185, and the proposed business combination between Big Cypress and SAB. These statements are based on the current expectations of SAB and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict, will differ from assumption and are beyond the control of SAB.

https://www.prnewswire.com/news-releases/big-cypress-acquisition-corp-announces-special-meeting-of-stockholders-to-approve-business-combination-with-sab-biotherapeutics-301383620.html

SABS: Engineered Immunity

Corporate Profile
SAB Biotherapeutics is a clinical-stage biopharmaceutical company leveraging its novel DiversitAb™ platform to produce a new class of specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors. By harnessing the native human antibody immune response, SAB’s platform enables a scalable and reliable production of these highly-efficacious polyclonal therapies with the potential to address the emergence, mutation, and diversity of modern health challenges including COVID-19, seasonal influenza, Type 1 diabetes, and cancers. The Company’s lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic for the treatment of COVID-19 advancing as part of the NIH’s ACTIV-2 protocol, and SAB-176, a multivalent, broadly neutralizing fully-human polyclonal antibody therapeutic candidate designed to bind to Type A and B viruses. Additional pre-clinical product candidates are in development for autoimmune diseases, including SAB-142 for Type 1 Diabetes and organ transplant induction/rejection, and SAB-181 for immune globulin (IgG) mediated diseases.

https://ir.sabbiotherapeutics.com/